Cover
Cover | Sep. 13, 2023 |
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | On September 14, 2023, First Wave BioPharma, Inc. (the "Company") filed a Current Report on Form 8-K (the "Prior 8-K") to report the Company's entrance into a license agreement (the "License Agreement"), dated September 13, 2023, by and between the Company and Sanofi. The Company is filing this amendment to the Prior 8-K in order to file herewith, as Exhibit 10.1, the License Agreement. The Prior 8-K otherwise remains unchanged. |
Document Period End Date | Sep. 13, 2023 |
Entity File Number | 001-37853 |
Entity Registrant Name | First Wave BioPharma, Inc. |
Entity Central Index Key | 0001604191 |
Entity Tax Identification Number | 46-4993860 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 777 Yamato Road |
Entity Address, Address Line Two | Suite 502 |
Entity Address, City or Town | Boca Raton |
Entity Address, State or Province | FL |
Entity Address, Postal Zip Code | 33431 |
City Area Code | 561 |
Local Phone Number | 589-7020 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Trading Symbol | FWBI |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |